Review Article

Ablative Therapy for Esophageal Dysplasia and Early Malignancy: Focus on RFA

Rebecca Tuttle, Steven J. Nurkin, and Steven N. Hochwald

Roswell Park Cancer Institute Elm & Carlton Streets, Buffalo, NY 14263, USA

Correspondence should be addressed to Steven N. Hochwald; steven.hochwald@roswellpark.org

Received 27 February 2014; Accepted 7 July 2014; Published 21 July 2014

Academic Editor: Stephen Grobmyer

Copyright © 2014 Rebecca Tuttle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ablative therapies have been utilized with increasing frequency for the treatment of Barrett’s esophagus with and without dysplasia. Multiple modalities are available for topical ablation of the esophagus, but radiofrequency ablation (RFA) remains the most commonly used. There have been significant advances in technique since the introduction of RFA. The aim of this paper is to review the indications, techniques, outcomes, and most common complications following esophageal ablation with RFA.

1. Introduction

Barrett’s esophagus (BE), with a reported prevalence of 1–6% in the general population, is intestinal metaplasia (IM) of the esophageal epithelium resulting from repeated mucosal injury secondary to chronic esophageal reflux [1, 2]. Histologically, this is defined as columnar replacement of the esophageal squamous epithelium with the demonstration of intestinal goblet cells [3]. BE is a premalignant condition with serial progression from metaplasia to low grade dysplasia (LGD) to high grade dysplasia (HGD) to early cancer to invasive cancer. The reported rate of Barrett’s progression to malignancy is 0.5% per year [3]. Once the progression to esophageal cancer is complete, the overall 5-year survival for esophageal cancer is 38%, 20%, and 3% for localized, regional, and distant disease, respectively. This reinforces the importance of continued surveillance and aggressive treatment of Barrett’s esophagus and esophageal dysplasia [4]. Although BE is widely prevalent in the U.S. population, the progression to malignancy is only found in a fraction of patients. The difficulty lies with identifying this fraction for aggressive screening.

In a recent survey of 236 gastroenterologists, the current practices for patient with Barrett’s esophagus with and without dysplasia were reported. Eighty-five percent of gastroenterologists surveyed were in community practice. For Barrett’s without dysplasia, 86% recommended surveillance, 12% performed ablation, and 3% offered no intervention. For Barrett’s with low-grade dysplasia, 56% recommended surveillance, 26% performed ablation in all patients, and 18% performed ablation selectively. For Barrett’s with high-grade dysplasia, 58% referred patients to a specialized center, 13% performed ablation in all patients, and 25% performed ablation selectively. Radiofrequency ablation (RFA) was the most common technique utilized (39%) followed by EMR (17%) [5].

Traditionally, the treatment for patients with HGD associated with Barrett’s esophagus was esophagectomy given the concern for occult malignancy. However, the morbidity and mortality rates associated with open esophagectomy are 42% and 3%, respectively [6]. Even with the advent of the minimally invasive esophagectomy, the morbidity and mortality are not trivial with a reported mortality of 2% and morbidities including pneumonia (4.9%) and anastomotic leak (7.8%) [7]. The reported mortality for the endoscopic management of esophageal dysplasia and early cancer is 0.4% [8]. For this reason, the interest in endoscopic management of esophageal dysplasia and early cancer has continued to rise. In a recent review, Wu et al. investigated the difference between endotherapy and esophagectomy for the treatment of Barrett’s esophagus with high-grade dysplasia and intramucosal cancer. They found no significant difference for neoplasia remission rate, overall survival at 1, 3, and 5 years, and neoplasia-related mortality risk. Patients treated with
Table 1: Ablative techniques.

| Esophageal ablative technique | Method                                                                                                                                                                                                 | Frequency of treatment | Complete eradication of intestinal metaplasia | Complete eradication of low grade dysplasia | Complete eradication of high grade dysplasia | Common complications (%) |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|---------------------------------------------|------------------------------------------|--------------------------------------------|--------------------------|
| RFA¹                         | Endoscopic balloon creates high frequency current which causes topical destruction of tissues                                                                                                         | q2-3 months until resolution | 54–97%                                      | 80–100%                                  | 81–90%                                    | Stricture (2–6%), hemorrhage |
| PDT²                         | Photosensitizer given prior to procedure allows the application of a specific wavelength of light to cause creation of oxygen free radicals and topical destruction of tissues                                      | 1-2 treatments, often followed by Nd:Yag laser therapy | 52%                                          | 93%                                       | 77%                                        | Photosensitivity, Stricture (30%) |
| APC³                         | Argon gas is passed through endoscope, monopolar current conducts through gas, and resulting heat causes topical destruction of tissues                                                                 | q8 week treatments      | 0–55%                                       | —                                         | 76%                                        | Stricture (15%)          |
| Cryotherapy⁴                 | Topical application of coolants causes destruction of tissues                                                                                                                                          | 3–5 treatments          | 57–84%                                      | 87%                                       | 97%                                        | Stricture (9%)          |

Description of common ablative techniques: ¹[28–31] ²[16,17] ³[23, 26, 32, 33] ⁴[34–36].

Endotherapy had higher incidence of neoplasia recurrence (RR 9.50) but fewer major adverse events (RR 0.38) [9]. This reinforces the use of endoscopic ablative therapies as an alternative to the traditional surgical approach in the appropriate patient population. Here, we complete a review of the endoscopic management of esophageal dysplasia and early cancer with a focus on radiofrequency ablation and its outcomes.

2. Review

2.1. Patient Evaluation. The initial evaluation of patients with BE begins with high resolution endoscopy for thorough evaluation of disease. Patients’ visible abnormalities are then characterized using the Paris classification [10, 11]. The BE segment is further characterized using the Prague-CM-classification including the length of the circumferential segment and the maximal extent of the Barrett’s esophagus segment [12]. Four quadrant biopsies are taken every 1 cm for the length of the Barrett’s segment [13]. Raised or nodular lesions are resected with endoscopic mucosal resection (EMR) prior to consideration for further ablative therapy. There is significant controversy regarding further preoperative imaging including CT or EUS for patients with HGD or early cancer. The likelihood of identifying metastatic or nodal disease in these patients is exceedingly low questioning the utility of additional work up and evaluation [14]. However, EUS to rule out more advanced disease is appropriate and performed in most centers prior to consideration of ablation.

Biopsy specimens should be evaluated by an experienced gastrointestinal pathologist. The Vienna classification is used for description of biopsy samples [15]. Patients are then considered candidates for further ablative therapy of flat areas of dysplasia if biopsies and EMR specimens are negative for intramucosal cancer without evidence of submucosal invasion. In addition, early cancerous lesions should be well- or moderately-differentiated without evidence of lymphovascular invasion.

2.2. Endoscopic Ablative Therapies. Alternative ablative techniques for esophageal dysplasia include photodynamic therapy (PDT), argon plasma coagulation (APC), and spray cryotherapy, most commonly (Table 1). In a series of 103 patients treated with photodynamic therapy followed by Nd:YAG laser during long-term follow-up, elimination rates were reported as 92.9% for LGD, 77.5% for HGD, and 44.4% for early cancer. Nd:YAG laser was used during long-term follow-up for ablation of recurrent or residual metaplasia or dysplasia. The reported overall [16] stricture rate was 30% [16]. In a subsequent partially-blinded randomized trial, Overholt et al. compared PDT to PPI therapy alone and found a 77% dysplasia response compared to 39% with PPI therapy alone [17]. Results were similar at 5 year follow-up [18]. There were no reported recurrences in the above studies with the addition of Nd:YAG laser therapy. There were 4.6% of patients presenting with subsquamous intestinal metaplasia noted on follow-up [16]. One of the major adverse effects of photodynamic therapy is the profound photosensitivity, which can last for 8 weeks [19–21]. In a direct comparison of RFA to PDT, Ertan et al. reported a complete histologic resolution of Barrett’s dysplasia in 54.5% of patients undergoing PDT and 88.7% of patients undergoing RFA. There was one serious adverse event in the PDT group (esophageal perforation) with none reported in the RFA group, and the cost of PDT was five times more than the cost of RFA supporting their preferred use of RFA [22].
APC involves the passage of argon gas through an endoscope with the conduction of monopolar current through the gas. This allows for heat destruction of the topical tissues. There is no set depth of penetration for APC as compared to RFA. In a prospective, randomized trial of APC versus endoscopic surveillance, 51 patients were followed for a year after undergoing APC or surveillance alone. Initially, 25 of the 26 patients treated with APC had a 95% resolution of IM. No patients had a complete eradication of IM. At a year follow-up, 14 of 23 patients had 95% regression of IM and 9 of 23 had complete regression [23]. This study was followed with a combined analysis of two randomized trials. A total of 129 patients were included and randomized to APC versus surveillance. The initial ablation of >95% of IM was achieved in 61 of 63 patients in the APC arm. This persisted in 21 of 32 patients at long-term follow-up (>84 months). The progression to HGD was 1 in the APC group compared to 3 in the surveillance group. Similarly, the progression to LGD was 1 in the APC group compared to 6 in the surveillance group [24]. Several studies have been completed comparing APC to PDT for the eradication of both intestinal metaplasia and dysplasia. Results from all have demonstrated similar responses for both therapies with a slightly improved response with PDT but at a higher overall cost [25–27].

Cryotherapy has also been used for the ablation of esophageal dysplasia and early cancer. It has been proven to be a safe and well-tolerated form of therapy [34, 39]. Gosain et al. reported on 32 patients with HGD in the setting of BE who underwent spray cryotherapy; 100% of patients had complete eradication of HGD at 2 years, and 84% of patients had complete eradication of IM in the same time period. Recurrence of HGD was documented in 6 patients with all but 1 patient achieving repeat complete eradication with subsequent treatments. The reported stricture rate was 9% [35]. In a larger study, Shaheen et al. evaluated 98 patients with HGD. After 10.5 months of follow-up, reported responses were 97% for eradication of HGD, 87% for eradication of dysplasia, and 57% for eradication of metaplasia. Buried glands were found in 3% of patients [36]. In a study examining the recurrence of dysplasia following spray cryotherapy, 30% of patients developed recurrent disease in a median of 6.5 months with just under 10% going on to develop a second recurrence. Ninety-two percent of these patients were able to go on to achieve complete response with repeat therapy [40].

3. RFA

3.1. Indications for RFA. RFA’s primary indication was dysplastic BE, but given the believed natural history of nondysplastic BE progressing to dysplastic BE, there are some who advocate the use of RFA for all patients with BE. Hur et al. examined the effectiveness and cost effectiveness of surveillance endoscopy with surgery when cancer was detected, surveillance with RFA when HGD was detected, and initial RFA when Barrett’s was detected followed by endoscopic surveillance. For HGD, they found RFA to be more effective and cost effective than surveillance followed by surgery. For nondysplastic Barrett’s, they found surveillance until HGD to be more effective and cost effective than initial RFA. For LGD, they stated that for stable disease, RFA may be effective as an initial treatment, but the data was not conclusive [41].

Pohl et al. examined the cost effectiveness in the United Kingdom of endoscopic therapy versus esophagectomy for early esophageal cancer. The reported costs of endoscopic therapy were $17,000.00 with 4.88 quality-adjusted life years. The costs for esophagectomy were $28,000.00 with 4.59 quality-adjusted life years. Varying the recurrence rates following endoscopic therapy did not affect the outcomes. The risk of lymph node metastasis with esophagectomy needed to exceed 25% for esophagectomy to be the favored treatment option [42]. Similarly, cost effectiveness models comparing RFA to esophagectomy for patients with high grade dysplasia have demonstrated improved cost effectiveness for RFA [43].

3.2. Method for Radiofrequency Ablation. The most commonly used method for esophageal RFA is circumferential balloon ablation using the Barrx system, formerly the HALO system (Covidien, Dublin, Ireland). Initial circumferential RFA is completed with the Barrx260-balloon. The RF energy is directed uniformly to a depth of 0.5 mm. The balloons are available in varying sizes to allow for complete tissue contact. Following circumferential RFA, or in the absence of circumferential BE, the Barrx30-balloon or the Barrx60-balloon can be utilized for site-directed radiofrequency ablation (Figure 1). Van Vilsteren et al. reported alternative methods for circumferential RFA. The standard procedure involves circumferential RFA, removal of the device for a cleaning phase, and then a second circumferential RFA. Van Vilsteren and colleagues compared this standard approach to cleaning the device without removal and to two circumferential ablations without cleaning. Ultimately, they found that the procedure could be modified to forego or simplify the cleaning phase without effect on outcomes [44]. These procedures are generally performed on an outpatient basis and require conscious sedation only. Post procedure, patients are recommended to continue a liquid diet for 24 hours. Patients may experience chest pain and dysphagia following the procedure and are generally provided with liquid pain medications prior to discharge. RFA may be repeated every 2 to 3 months until complete resolution of dysplasia and intestinal metaplasia. Following the final RFA treatment, patients should be reexamined in 2 months with biopsies taken to confirm complete resolution. Ongoing surveillance schedules following complete resolution are variable, but most commonly patients are seen every 6 months for a total of one year and yearly thereafter [45].

3.3. Addition of EMR. The Barrx system requires flat epithelium to maintain tissue contact and complete uniform ablation [28]. For this reason, RFA alone cannot be used to treat nodular BE or early esophageal cancer. The addition of EMR prior to ablation broadens the application of RFA. Pouw et al. completed a multicenter, prospective cohort study of 24 patients with Barrett’s esophagus and HGD or early cancer. Visible lesions were resected with EMR followed by
Figure 1: Radiofrequency ablation in the Treatment of Barrett's Esophagus [29]. Figure copied with permission from Shaheen et al. (a) Endoscopic photograph of Barrett's esophagus. (b) Circumferential radiofrequency ablation balloon. (c) Endoscopic photograph of deflated RFA balloon within the esophagus prior to ablation. (d) Endoscopic photograph of the esophagus with immediate post-RFA treatment effect. (e) Focal radiofrequency ablation device. (f) Endoscopic photograph of residual Barrett's esophagus (circled) 2 months status after ablation. (g) Endoscopic photograph of residual Barrett's esophagus status after repeat ablation [29].

RFA of remaining intestinal metaplasia. EMR was repeated for persistent areas of intestinal metaplasia following RFA. Complete eradication of neoplasia was reported in 95% initially and 100% following repeat “escape” EMR. Complete eradication of metaplasia was reported in 88% initially and 96% following repeat EMR. After a median follow-up of 22 months, no neoplasia recurred [Pouw 2010]. Kim et al. completed a retrospective analysis of EMR prior to RFA in nodular lesions. They identified 65 patients treated with EMR prior to RFA and found no difference in efficacy or safety outcomes with EMR prior to RFA in nodular Barrett’s compared to RFA alone in nonnodular Barrett’s [46]. Further advancement of this technique has allowed RFA use in the setting of early intramucosal adenocarcinoma. EMR is essential in these patients to adequately characterize the lesion and ensure the absence of advanced esophageal adenocarcinoma. At the completion of EMR, all mucosal surfaces should be flat and residual areas of dysplasia should be biopsied to ensure the absence of invasive cancer. RFA may then be completed 6 to 8 weeks following EMR.

3.4. Outcomes of RFA Therapy. The AIM Dysplasia Trial was a multicenter, sham-controlled trial of 127 patients with dysplastic BE. Patients were assigned to either RFA or sham procedure. Outcomes analyzed included complete eradication of dysplasia and IM (Table 2). In the intention to treat analysis, 90.5% of patients with low grade dysplasia...
### Table 2: Primary and secondary outcomes at follow-up.

| Outcome and analysis | Radiofrequency ablation | Sham procedure | Relative risk (95% CI) | \( P \) value | Number needed to treat† |
|----------------------|--------------------------|----------------|------------------------|----------------|------------------------|
| **Primary outcome**  |                          |                |                        |                |                        |
| Complete eradication of intestinal metaplasia (all patients) | | | | | |
| Intention-to-treat   | 65/84 (77)               | 1/43 (2)       | 33.3 (4.8–231.7)       | <0.001         | 1.3                    |
| Per-protocol         | 65/78 (83)               | 1/39 (3)       | 32.5 (4.6–225.5)       | <0.001         | 1.2                    |
| Complete eradication of dysplasia (low-grade dysplasia) | | | | | |
| Intention-to-treat   | 38/42 (90)               | 5/22 (23)      | 4.0 (1.8–10.7)         | <0.001         | 1.5                    |
| Per-protocol         | 38/40 (95)               | 5/19 (26)      | 3.6 (1.7–7.7)          | <0.001         | 1.5                    |
| Complete eradication of dysplasia (high-grade dysplasia) | | | | | |
| Intention-to-treat   | 34/42 (81)               | 4/21 (19)      | 4.2 (1.7–10.4)         | <0.001         | 1.6                    |
| Per-protocol         | 34/38 (90)               | 4/20 (20)      | 4.5 (1.8–10.8)         | <0.001         | 1.4                    |
| **Secondary outcomes** |                          |                |                        |                |                        |
| Complete eradication of intestinal metaplasia (high-grade dysplasia) | | | | | |
| Intention-to-treat   | 31/42 (74)               | 0/21           | ND                     | <0.001         | 1.4                    |
| Per-protocol         | 31/38 (82)               | 0/20           | ND                     | <0.001         | 1.2                    |
| Complete eradication of intestinal metaplasia (low-grade dysplasia) | | | | | |
| Intention-to-treat   | 34/42 (81)               | 1/22 (4)       | 17.8 (2.6–121.5)       | <0.001         | 1.3                    |
| Per-protocol         | 34/40 (85)               | 1/19 (5)       | 16.1 (2.4–109.3)       | <0.001         | 1.3                    |
| Complete eradication of dysplasia (all patients) | | | | | |
| Intention-to-treat   | 72/84 (86)               | 9/43 (21)      | 4.1 (2.3–7.4)          | <0.001         | 1.5                    |
| Per-protocol         | 72/78 (92)               | 9/39 (23)      | 4.0 (2.2–7.1)          | <0.001         | 1.4                    |
| **Progression of dysplasia** | | | | | |
| Any                  | 3/84 (4)                 | 7/43 (16)      | 02 (0.1–0.8)           | 0.03           | 7.9                    |
| Low-grade to high-grade | 2/42 (5)              | 3/22 (14)      | 0.3 (0.1–1.9)          | 0.33           | 11.3                   |
| Low-grade to cancer  | 0/42                     | 0/22           | ND                     | ND             | NA                     |
| High-grade to cancer | 1/42 (2)                 | 4/21 (19)      | 0.1 (0.01–1.0)         | 0.04           | 6.0                    |
| High-grade or low-grade to cancer | 1/84 (1) | 4/43 (9) | 0.1 (0.01–1.1) | 0.045 | 12.3 |
| Biopsy specimen free of intestinal metaplasia at 12 mo | | | | | |
| All patients         | 2670/2724 (98)           | 673/1164 (58)  | 1.7 (1.6–1.8)          | <0.001         | NA                     |
| Low-grade-dysplasia subgroup | 1228/1260 (98) | 313/550 (57) | 1.7 (1.6–1.8) | <0.001 | NA |
| High-grade-dysplasia subgroup | 1442/1464 (98) | 360/614 (59) | 1.7 (1.6–1.8) | <0.001 | NA | |
| **Secondary outcomes** |                          |                |                        |                |                        |
| Chest-pain score on day 1‡ | | | | | |
| All patients         |                          |                |                        | <0.001         | NA                     |
| No. of patients      | 81                        | 40             |                        |                | NA                     |
| Median               | 23                        | 0              |                        |                | NA                     |
| Interquartile range  | 0–51                      | 0–0            |                        |                | NA                     |
| Low-grade dysplasia  |                          |                |                        | <0.001         | NA                     |
| Number of patients   | 40                        | 20             |                        |                | NA                     |
| Median               | 26                        | 0              |                        |                | NA                     |
| Interquartile range  | 4–48                      | 0–0            |                        |                | NA                     |
Table 2: Continued.

| Outcome and analysis | Radiofrequency ablation | Sham procedure | Relative risk (95% CI) | P value | Number needed to treat† |
|----------------------|--------------------------|----------------|------------------------|---------|-------------------------|
| High-grade dysplasia |                          |                |                        |         | <0.001 NA               |
| Number of patients   | 41                       | 20             |                        |         |                         |
| Median               | 22                       | 0              |                        |         |                         |
| Interquartile range  | 0–57                     | 0–0            |                        |         |                         |

*NA denotes not applicable, and ND not done.
†The number needed to treat refers to the number of patients who would need to be treated with radiofrequency ablation to prevent one outcome failure (the inverse of the absolute risk reduction).
‡Chest pain was measured on a visual-analogue scale of 0 to 100, with higher scores indicating a greater severity of pain.

Table 3: Esophageal RFA results summary.

| Series                  | Mean/median length of BE (cm) | Mean/median number of treatments required | Follow-up interval (months) | Complete eradication of intestinal metaplasia (%) | Complete eradication of low-grade dysplasia (%) | Complete eradication of high-grade dysplasia (%) | Rates of progression (%) | Complication rates (%) |
|-------------------------|-------------------------------|------------------------------------------|----------------------------|--------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------|------------------------|
| Ganz et al., 2008 [28]  | 6                             | 1                                        | 12                         | 54.3                                             | 80.4                                          | 90.2                                          | —                       | 0.7                    |
| Fleischer et al., 2008 [37] | 3.2                           | 1.5                                      | 30                         | 97                                               | —                                             | —                                             | —                       | 0                     |
| Shaheen et al., 2009 [29] | 5.3 ś                         | Up to 4                                  | 12                         | 77.4                                             | 90.5                                          | 81.0                                          | 4                       | 6.0                    |
| Fleischer et al., 2010 [38] | 3.2 ś                        | 3.4                                      | 60                         | 92                                               | —                                             | —                                             | —                       | 0                     |
| Lyday et al., 2010 [30] | 3                             | 1.8–2.1                                  | 20                         | 77                                               | 100                                           | —                                             | —                       | 1.1                    |

*5.3 is mean and for HGD, 4.6 for LGD.

had complete eradication compared to 22.7% in the sham control group. Similarly, 81% of patients with HGD had complete eradication of dysplasia compared to 19% of patients in the sham control group. 77.4% of patients had complete eradication of IM compared to 2.3% in the control group. The RFA group had less disease progression and fewer cancers (1.2% versus 9.3%) [29].

The AIM II Trial examined the use of RFA in nondysplastic BE. This study reported on 70 patients with short-segment BE and followed them for 2.5 years following therapy. Circumferential ablation was completed initially and repeated 4 months later if there was residual disease present. Patients were all maintained on PPI therapy after procedure. Completed eradication of IM was present in 70% of patients at 12 months and 98% of patients at 30 months with repeated treatment at 12 months if IM was detected. No serious adverse events were reported [37]. Follow-up after 5 years demonstrated complete eradication of BE in 92% of available patients with those who experienced recurrence or residual disease obtaining a complete response with repeat treatment, again, no adverse events were reported [38].

Ganz et al. conducted a multicenter U.S. registry at 16 academic and community centers over a 3-year period. Patients with HGD and IM were included. A total of 142 patients underwent circumferential RFA, with a median of 1 session. No serious adverse events were encountered, 1 patient had an asymptomatic stricture, and there was no evidence of buried glands. Complete response of HGD was reported for 90.2% of patients, complete response of dysplasia was reported for 80.4% of patients, and complete response on IM was reported for 54.3% of patients [28].

The above studies were primarily conducted at tertiary referral centers. Lyday et al. conducted a multicenter registry in community-based gastroenterology practices. They performed step-wise RFA with subsequent follow-up and biopsies. There were a total of 429 patients treated with and without dysplasia. No serious adverse events were reported. Surveillance immediately following treatment demonstrated complete eradication of dysplasia in 89% and complete eradication of IM in 72%. Those patients followed for at least one year following therapy had complete eradication of dysplasia in 100% and complete eradication of IM in 77% with a median follow-up of 20 months [30] (Table 3).

3.5. RFA in the Treatment of Long and Ultra-Long Barrett’s Esophagus. There has been questions on the use of RFA with or without EMR for the treatment of ultra-long segment BE (>8 cm). Dulai et al. reported similar outcomes for patients
with both long segment Barrett's (3 to 8 cm) and ultra-
long segment Barrett's, with eradication rates for dysplasia
(>88%) and IM (>77%) for both. Patients with ultra-long
segment BE did require more RFA sessions and had decreased
durability of eradication, 65% versus 82%. On multivariate
regression analysis, increasing Barrett's length was associated
with a reduced likelihood of eradicating metaplasia but not
dysplasia [47]. Herrero et al. presented similarly successful
results for lesions greater than 10 cm. They had complete
response of neoplasia in 83% and complete response of IM in
79% without any serious complications. Minor complications
were reported in 15% [48].

3.6. Impact of Fundoplication on RFA. There were initial
concerns over the impact that prior fundoplication would
have on the ability to complete RFA safely and the expected
outcomes. Shaheen et al. queried the U.S. RFA Registry for
patients with and without prior fundoplication. They identi-
fied 5,537 total patients undergoing RFA and 301 patients
who had undergone prior fundoplication. In their review, rates
of complete eradication of IM and dysplasia were similar in both
groups. Complications were also not statistically different
[49]. There have been reports of improved response durability
with fundoplication added to ablative therapy [50].

3.7. Complications of RFA. The most common complication
associated with esophageal RFA is stricture formation with a
reported incidence of 5–9% [29, 30, 51–53]. Hemorrhage has
also been reported, although less commonly [29]. These are
both generally managed endoscopically.

At the outset of RFA, there were initial concerns
for postprocedure esophageal dysmotility and function.
Beaumont et al. reported on the effects of RFA on inner
esophageal diameter, compliance and motility. They followed
12 patients with intramuscular adenocarcinoma or HGD who
underwent EMR of visible lesions followed by a maximum
of 5 RFA sessions. All patients in their study had complete
eradication of dysplasia and IM. Lower esophageal sphincter
pressure and length and esophageal contraction amplitude
were not affected by RFA. Esophageal compliance was noted
to be decreased in patients with BE when compared to healthy
volunteers, but not affected by RFA [54]. Similar reports have
demonstrated no significant changes in esophageal motility
or 24-h pH-impedance measurements before and after RFA
[55].

3.8. Esophageal Resistance to Ablation. The reasons for resis-
tance to RFA are not entirely clear. Poor response is defined
as less than 50% reduction in Barrett's after 3 months from
the initiation of therapy [56]. Gupta et al. reported patients'
age and length of the Barrett's segment to be associated with
longer time to complete remission of Barrett's changes [57].
Similar studies have also identified length of Barrett's seg-
ment, size of hiatal hernia, and incomplete healing between
RFA treatments to be associated with increased failed therapy
[53, 58]. Zeki et al. suggested that clonal selection via the
RFA allows for the subsequent overgrowth of resistant clonal
populations and the clinical picture of recurrent or resistant
BE [59]. Looking further at patient characteristics predictive
of poor response to RFA, van Vilsteren et al. identified
278 patients from 14 centers who underwent circumferential
balloon-based RFA. Characteristics they identified as predic-
tive of poor response were active reflux esophagitis, endo-
scopic resection scar regeneration with Barrett's epithelium,
esophageal narrowing pre-RFA, and years of neoplasia pre-
RFA [56]. This helps to highlight those patients who would be
at increased risk for failure of therapy.

3.9. Recurrence following Ablation. Recurrence of BE follow-
complete eradication is reported as 5% per year [60].
Korst et al. described 3 distinct patterns of recurrence follow-
ing RFA of BE: endoscopically invisible intestinal metaplasia
underneath neosquamous epithelium, visible recurrence in
the tubular esophagus, and intestinal metaplasia of the
gastroesophageal junction [61]. There has been significant
discussion of the concept of “buried glands,” or intestinal
metaplasia beneath neosquamous epithelium. Concerns
include inadequate surveillance, sufficient depth of biopsy,
and increased malignant potential.

There has been investigation into esophageal acid expo-
sure and its impact on RFA effectiveness. A retrospective
analysis of 45 patients' status after RFA was completed with
esophageal pH monitoring. Twenty-nine percent of patients
exhibited severe esophageal acid exposure despite adequate
therapy. Additionally, they found that those patients with
normal esophageal acid exposure had greater reduction in BE
surface area and increased rates of complete eradication [62].
Similarly, Krishnan et al. completed a prospective review of
37 patients and found that predominantly weak acidic reflux
despite twice daily therapy was associated with an increased
incidence of persistent IM after ablation in patients with BE
[58]. O'Connell and Velanovich reported on the durability
of response to RFA with and without fundoplication. While
the study included only 47 patients with long-term follow-up,
they found that patients who had undergone fundoplication
were more likely to have a durable response than those treated
with proton pump inhibitor therapy [50]. Based on these data,
it is likely that persistent acid reflux predisposes to recurrent
BE after RFA.

3.10. Mucosal Resistance following RFA. Mucosal resistance
is a concept introduced in those patients undergoing
esophageal RFA. There was a question regarding the ability
to adequately survey the postablative esophagus secondary
to scarring and subsequent fibrosis. This is in concert with
the concept of “buried glands” or subsquamous IM. Following
RFA, the development of neosquamous epithelium can allow
for the collection of metaplastic nests of tissue beneath
the epithelial lining of the esophagus. First, Overholt et al.
analyzed the depths of esophageal biopsies before and after
RFA to determine the percentage that contained lamina
propria and, therefore, an adequately representative sample.
Approximately 90% of biopsies in both ablated patients and
ablation-naive patients were adequate to detect all evident
intestinal metaplasia [63]. Similarly, follow-up of the AIM
Dysplasia Trial demonstrated adequate surveillance biopsies
in 80% of patients with the finding that biopsies on squamous surfaces were more likely to be inadequate than biopsies on columnar surfaces [64]. Yuan et al. reported a 15% incidence of buried IM following radiofrequency ablative therapy for BE. All of those patients were detected with standard biopsy and all IM underwent complete response following new or repeat RFA [65]. The 5-year follow-up of the AIM II Trial reported 85% of biopsies to contain lamina propria with no patients demonstrating buried glands [38].

3.11. Quality of Life following RFA. Shaheen et al. were the first to examine quality of life following RFA of the esophagus. This was analyzed from the AIM Trial in which patients were treated with RFA or sham therapy. In this population of patients, they found that, prior to any treatment, patients were worried about esophageal cancer and esophagectomy. Similarly, there were increased reports of depression, worry, and stress. Twelve months following therapy, those patients treated with RFA had significantly less worry and depression owing to the perceived benefit of RFA on the treatment of esophageal disease and the decreased risk of esophageal cancer [66].

4. Conclusion

Endoscopic intervention continues to be a safe and preferred alternative to radical surgery for esophageal dysplasia and intramucosal carcinoma. The most common practice pattern for the use of ablative therapies, particularly RFA, is following endoscopic mucosal resection for the assessment of any invasive malignancy. RFA has reported results superior to APC and PDT. It is generally well-tolerated with few serious, adverse events reported. When compared to PDT, RFA is more cost effective [22] and foregoes the subsequent photo sensitivity. While cryotherapy has acceptable initial results, there has been a suggestion of a higher recurrence rate (up to 30%) associated with the procedure [40]. Despite the method utilized for complete eradication of metaplasia and dysplasia, patients remain at risk for recurrence of disease. For this reason, continued surveillance is warranted.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] J. Ronkainen, P. Aro, T. Storskrubb et al., “Prevalence of Barrett’s esophagus in the general population: an endoscopic study,” Gastroenterology, vol. 129, no. 6, pp. 1825–1831, 2005.
[2] N. J. Shaheen and J. E. Richter, “Barrett’s oesophagus,” The Lancet, vol. 373, no. 9666, pp. 850–861, 2009.
[3] S. J. Spechler, P. Sharma, R. F. Souza, J. M. Inadomi, and N. J. Shaheen, “American gastroenterological association technical review on the management of Barrett’s oesophagus,” Gastroenterology, vol. 140, no. 3, pp. e16–e52, 2011.
[4] Survival rates for cancer of the esophagus by stage, 2013, http://www.cancer.org/cancer/esophaguscancer/detailedguide/esophagus-cancer-survival-rates.
[5] M. Singh, N. Gupta, S. Gaddam et al., “Practice patterns among U.S. gastroenterologists regarding endoscopic management of Barrett’s esophagus,” Gastrointestinal Endoscopy, vol. 78, no. 5, pp. 689–695, 2013.
[6] J. B. F. Hulscher, J. W. Van Sandick, A. G. E. M. De Boer et al., “Extended transthoracic resection compared with limited transthiatal resection for adenocarcinoma of the esophagus,” The New England Journal of Medicine, vol. 347, no. 21, pp. 1662–1669, 2002.
[7] R. M. Levy, D. Trivedi, and J. D. Luketich, “Minimally Invasive Esophagectomy,” Surgical Clinics of North America, vol. 92, no. 5, pp. 1265–1285, 2012.
[8] D. Menon, T. Stafinski, H. Wu, D. Lau, and C. Wong, “Endoscopic treatments for Barrett’s esophagus: a systematic review of safety and effectiveness compared to esophagectomy,” BMC Gastroenterology, vol. 10, article 11, 2010.
[9] J. Wu, Y.-M. Pan, T.-T. Wang, D.-J. Gao, and B. Hu, “Endotherapy versus surgery for early neoplasia in Barrett’s esophagus: a meta-analysis,” Gastrointestinal Endoscopy, vol. 79, no. 2, pp. 233.e2–241.e2, 2014.
[10] “The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002,” Gastrointestinal Endoscopy, vol. 58, no. 6, supplement, pp. S3–S43, 2003.
[11] A. Axon, M. D. Diebold, M. Fujino et al., “Update on the Paris classification of superficial neoplastic lesions in the digestive tract,” Endoscopy, vol. 37, no. 6, pp. 570–578, 2005.
[12] P. Sharma, J. Dent, D. Armstrong et al., “The development and validation of an endoscopic grading system for Barrett’s esophagus: the prague C & M criteria,” Gastroenterology, vol. 131, no. 5, pp. 1392–1399, 2006.
[13] B. J. Reid, P. L. Blount, Z. Feng, and D. S. Levine, “Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia,” American Journal of Gastroenterology, vol. 95, no. 11, pp. 3089–3096, 2000.
[14] O. Pech, A. May, E. Günter, L. Gossner, and C. Ell, “The impact of endoscopic ultrasound and computed tomography on the TNM staging of early cancer in Barrett’s esophagus,” The American Journal of Gastroenterology, vol. 101, no. 10, pp. 2223–2229, 2006.
[15] R. J. Schlemper, R. H. Riddell, Y. Kato et al., “The vienna classification of gastrointestinal epithelial neoplasia,” Gut, vol. 47, no. 2, pp. 251–255, 2000.
[16] B. F. Overholt, M. Panjehpour, and D. L. Halberg, “Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results,” Gastrointestinal Endoscopy, vol. 58, no. 2, pp. 183–188, 2003.
[17] B. F. Overholt, C. J. Lightdale, K. K. Wang et al., “Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial,” Gastrointestinal Endoscopy, vol. 62, no. 4, pp. 488–498, 2005.
[18] B. F. Overholt, K. K. Wang, J. S. Burdick et al., “Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia,” Gastrointestinal Endoscopy, vol. 66, no. 3, pp. 460–468, 2007.
[19] B. J. Qumseya, W. David, and H. C. Wolfsen, “Photodynamic therapy for Barrett’s esophagus and esophageal carcinoma,” Clinical Endoscopy, vol. 46, no. 1, pp. 30–37, 2013.
N. Shishkova, O. Kuznetsova, and T. Berezov, "Photodynamic therapy in gastroenterology," *Journal of Gastrointestinal Cancer*, vol. 44, no. 3, pp. 251–259, 2013.

S. Yano, S. Hirohara, M. Obata et al., "Current states and future views in photodynamic therapy," *Journal of Photochemistry and Photobiology C: Photochemistry Reviews*, vol. 12, no. 1, pp. 46–67, 2011.

A. Ertan, I. Zaheer, A. M. Correa, N. Thosani, and S. H. Blackmon, "Photodynamic therapy vs radiofrequency ablation for Barrett's dysplasia: efficacy, safety and cost-comparison," *World Journal of Gastroenterology*, vol. 19, no. 41, pp. 7106–7113, 2013.

T. Bright, D. I. Watson, W. Tam et al., "Prospective randomized trial of argon plasma coagulation ablation vs endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication," *Digestive Diseases and Sciences*, vol. 54, no. 12, pp. 2606–2611, 2009.

C. Sie, T. Bright, M. Schoeman et al., "Argon plasma coagulation ablation vs endoscopic surveillance of Barrett's esophagus: late outcomes from two randomized trials," *Endoscopy*, vol. 45, no. 11, pp. 859–865, 2013.

M. Hage, P. D. Sietsma, H. van Dekken et al., "5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial," *Gut*, vol. 53, no. 6, pp. 785–790, 2004.

K. Ragunath, N. Krasner, V. S. Raman, M. T. Haqqani, C. J. Phillips, and I. Cheung, "Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness," *Scandinavian Journal of Gastroenterology*, vol. 40, no. 7, pp. 750–758, 2005.

C. J. Kelly, R. Ackroyd, N. J. Brown, T. J. Stephenson, C. J. Stoddard, and M. W. R. Reed, "Endoscopic ablation of Barrett's oesophagus: a randomised-controlled trial of photodynamic therapy vs argon plasma coagulation," *Alimentary Pharmacology and Therapeutics*, vol. 20, no. 11-12, pp. 1289–1296, 2004.

R. A. Ganz, B. F. Overholt, V. K. Sharma et al., "Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry," *Gastrointestinal Endoscopy*, vol. 68, no. 1, pp. 35–40, 2008.

N. J. Shaheen, P. Sharma, B. F. Overholt et al., "Radiofrequency ablation in Barrett's esophagus with dysplasia," *The New England Journal of Medicine*, vol. 360, no. 22, pp. 2277–2288, 2009.

W. D. Lyday, F. S. Corbett, D. A. Kuperman et al., "Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry," *Endoscopy*, vol. 42, no. 4, pp. 272–278, 2010.

D. E. Fleischer and V. K. Sharma, "Endoscopic ablation of Barrett's esophagus using the Halo system," *Digestive Diseases*, vol. 26, no. 4, pp. 280–284, 2009.

R. Ackroyd, W. Tam, M. Schoeman, P. G. Devitt, and D. I. Watson, "Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery," *Gastrointestinal Endoscopy*, vol. 59, no. 1, pp. 1–7, 2004.

S. E. A. Attwood, C. J. Lewis, S. Caplin, K. Hemmings, and G. Armstrong, "Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus," *Clinical Gastroenterology and Hepatology*, vol. 1, no. 4, pp. 258–263, 2003.

B. D. Greenwald, J. A. Dumot, J. D. Horwhat, C. J. Lightdale, and J. A. Abrams, "Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus," *Diseases of the Esophagus*, vol. 23, no. 1, pp. 13–19, 2010.

S. Gosain, K. Mercer, W. S. Twaddell, L. Uradomo, and B. D. Greenwald, "Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results," *Gastrointestinal Endoscopy*, vol. 78, no. 2, pp. 260–265, 2013.

N. J. Shaheen, B. D. Greenwald, A. F. Peery et al., "Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia," *Gastrointestinal Endoscopy*, vol. 71, no. 4, pp. 680–685, 2010.

D. E. Fleischer, B. F. Overholt, V. K. Sharma et al., "Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up," *Gastrointestinal Endoscopy*, vol. 68, no. 5, pp. 867–876, 2008.

D. E. Fleischer, B. F. Overholt, V. K. Sharma et al., "Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial," *Endoscopy*, vol. 42, no. 10, pp. 781–789, 2010.

B. D. Greenwald, J. A. Dumot, J. A. Abrams et al., "Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy," *Gastrointestinal Endoscopy*, vol. 71, no. 4, pp. 686–693, 2010.

K. D. Halsey, J. W. Chang, A. Waldt, and B. D. Greenwald, "Recurrent disease following endoscopic ablation of Barrett's high-grade dysplasia with spray cryotherapy," *Endoscopy*, vol. 43, no. 10, pp. 844–848, 2011.

C. Hur, S. E. Choi, J. H. Rubenstein et al., "The cost effectiveness of radiofrequency ablation for Barrett's esophagus," *Gastroenterology*, vol. 143, no. 3, pp. 567–575, 2012.

H. Pohl, A. Sonnenberg, S. Strobel, A. Eckardt, and T. Rösch, "Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis," *Gastrointestinal Endoscopy*, vol. 70, no. 4, pp. 623–631, 2009.

P. C. Boger, D. Turner, P. Roderick, and P. Patel, "A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus," *Alimentary Pharmacology and Therapeutics*, vol. 32, no. 11-12, pp. 1332–1342, 2010.

F. G. I. van Vilsteren, K. N. Phoa, L. Alvarez Herrero et al., "Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase," *Clinical Gastroenterology and Hepatology*, vol. 11, no. 5, pp. 491–498, 2013.

F. G. I. van Vilsteren and J. J. G. H. M. Bergman, "Endoscopic therapy using radiofrequency ablation for esophageal dysplasia and carcinoma in Barrett's esophagus," *Gastrointestinal Endoscopy Clinics of North America*, vol. 20, no. 1, pp. 55–74, 2010.

H. P. Kim, W. J. Bulsiewicz, C. C. Cotton et al., "Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia," *Gastrointestinal Endoscopy*, vol. 76, no. 4, pp. 733–739, 2012.

P. S. Dulai, H. Pohl, J. M. Levenick, S. R. Gordon, T. A. MacKenzie, and R. I. Rothstein, "Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study," *Gastrointestinal Endoscopy*, vol. 77, no. 4, pp. 534–541, 2013.

L. A. Herrero, F. G. I. van Vilsteren, R. E. Prouw et al., "Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer
than 10 cm," *Gastrointestinal Endoscopy*, vol. 73, no. 4, pp. 682–690, 2011.

[49] N. J. Shaheen, H. P. Kim, W. J. Bulsiewicz et al., “Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA registry,” *Journal of Gastrointestinal Surgery*, vol. 17, no. 1, pp. 21–29, 2013.

[50] K. O’Connell and V. Velanovich, “Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus,” *Surgical Endoscopy and Other Interventional Techniques*, vol. 25, no. 3, pp. 830–834, 2011.

[51] R. J. Haidry, J. M. Dunn, M. A. Butt et al., “Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK national halo RFA registry,” *Gastroenterology*, vol. 145, no. 1, pp. 87–95, 2013.

[52] E. S. Orman, N. Li, and N. J. Shaheen, “Efficacy and durability of radiofrequency ablation for barrett’s esophagus: systematic review and meta-analysis,” *Clinical Gastroenterology and Hepatology*, vol. 11, no. 10, pp. 1245–1255, 2013.

[53] W. J. Bulsiewicz, H. P. Kim, E. S. Dellon et al., “Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett’s esophagus,” *Clinical Gastroenterology and Hepatology*, vol. 11, no. 6, pp. 636–642, 2013.

[54] H. Beaumont, J. J. Gondrie, B. P. McMahon et al., “Stepwise radiofrequency ablation of Barrett’s esophagus preserves esophageal inner diameter, compliance, and motility,” *Endoscopy*, vol. 41, no. 1, pp. 2–8, 2009.

[55] G. J. M. Hemmink, L. A. Herrero, A. Bogte et al., “Esophageal motility and impedance characteristics in patients with Barrett’s esophagus before and after radiofrequency ablation,” *European Journal of Gastroenterology & Hepatology*, vol. 25, no. 9, pp. 1024–1032, 2013.

[56] F. G. I. van Vilsteren, L. Alvarez Herrero, R. E. Pouw et al., “Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study,” *Endoscopy*, vol. 45, no. 7, pp. 516–525, 2013.

[57] M. Gupta, P. G. Iyer, L. Lutzke et al., “Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a us multicenter consortium,” *Gastroenterology*, vol. 145, no. 1, pp. 79.e1–86.e1, 2013.

[58] K. Krishnan, J. E. Pandolfino, P. J. Kahrilas, L. Keefer, L. Boris, and S. Komanduri, “Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation,” *Gastroenterology*, vol. 143, no. 3, pp. 576–581, 2012.

[59] S. S. Zeki, R. Haidry, T. A. Graham et al., “Clonal selection and persistence in dysplastic Barrett’s esophagus and intramucosal cancers after failed radiofrequency ablation,” *The American Journal of Gastroenterology*, vol. 108, no. 10, pp. 1584–1592, 2013.

[60] E. S. Orman, H. P. Kim, W. J. Bulsiewicz et al., “Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s Esophagus with radiofrequency ablation,” *American Journal of Gastroenterology*, vol. 108, no. 2, pp. 187–195, 2013.

[61] R. J. Korst, S. Santana-Joseph, J. R. Rutledge et al., “Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s esophagus,” *Journal of Thoracic and Cardiovascular Surgery*, vol. 145, no. 6, pp. 1529–1534, 2013.

[62] J. Akiyama, S. N. Marcus, and G. Triadafilopoulos, “Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus,” *Digestive Diseases and Sciences*, vol. 57, no. 10, pp. 2625–2632, 2012.

[63] B. F. Overholt, P. J. Dean, J. A. Galanko, and C. J. Lightdale, “Does ablative therapy for barrett esophagus affect the depth of subsequent esophageal biopsy as compared with controls?” *Journal of Clinical Gastroenterology*, vol. 44, no. 10, pp. 676–681, 2010.

[64] N. J. Shaheen, A. F. Peery, B. F. Overholt et al., “Biopsy depth after radiofrequency ablation of dysplastic Barrett’s esophagus,” *Gastrointestinal Endoscopy*, vol. 72, no. 3, pp. 490.e1–496.e1, 2010.

[65] J. Yuan, J. C. Hernandez, S. K. Ratuapli et al., “Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation,” *Endoscopy*, vol. 44, no. 11, pp. 993–997, 2012.

[66] N. J. Shaheen, A. F. Peery, R. H. Hawes et al., “Quality of life following radiofrequency ablation of dysplastic Barretts esophagus,” *Endoscopy*, vol. 42, no. 10, pp. 790–799, 2010.